

Impaired hemodynamics during LT, exacerbated by significant reperfusion syndrome, can unmask latent cardiovascular disease either perioperatively or immediately after transplant.

Pretransplant cardiovascular risk assessment in LT recipients still holds a degree of uncertainty in pretransplant evaluation because current noninvasive tests to evaluate subclinical coronary artery disease have low sensitivity.³ However, limited guidelines on the cardiac assessment of LT recipients have been reported.^{3,4}

In the case reported, VA-ECMO proved an effective extreme strategy in the event of severe refractory cardiogenic shock during LT, allowing us to complete the transplant and provide a bridge to myocardial revascularization.

We would like to point out that effective collaboration within teams and between specialties was crucial to

handle an extremely grave situation and facilitated positive patient outcome.

REFERENCES

1. Braun HJ, Pulcrano ME, Weber DJ, et al. The utility of ECMO after liver transplantation: experience at a high-volume transplant center and review of the literature. *Transplantation*. 2019;103:e319–e320.
2. Aufhauser DD Jr, Rose T, Levine M, et al. Cardiac arrest associated with reperfusion of the liver during transplantation: incidence and proposal for a management algorithm. *Clin Transplant*. 2013;27:185–192.
3. VanWagner LB, Harinstein ME, Runo JR, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. *Am J Transplant*. 2018;18:30–42.
4. Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. *Liver Transpl*. 2017;23:386–395.